4D Molecular Therapeutics, Inc.
NASDAQ:FDMTBiotechnology
+$0.16 today
- Market cap
- $596.08M
- Beta
- 2.76
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$2.36
Volume 0.81M
Average 0.77M
FDMT EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
4D Molecular Therapeutics, Inc.NASDAQ: FDMT
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$66.71M, compared with -$46.22M a year earlier. Trailing-twelve-month EBITDA was -$163.43M.
Context
- EBITDA amounted to 155.5% of revenue in FY2025, down 416501.3 pp from a year earlier.
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of -$235.14M (-77.5%) for the fiscal year ending Dec 2026, a slowdown from the +14.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$66.71M-638.6% QoQ
- Last fiscal yearDec 2025
- -$132.48M+14.1% YoY
- LTMMar 2026
- -$163.43M+3.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -44.3% | -33.4% | +10.9 pp |
| 1 year | +14.1% | -77.5% | -91.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (132.48M) USD
- Year-over-year change
- +14.1%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (132.48M) | +14.1% |
| FY2024 | 2024-12-31 | (154.16M) | -59.5% |
| FY2023 | 2023-12-31 | (96.63M) | +8.0% |
| FY2022 | 2022-12-31 | (105.09M) | -50.6% |
| FY2021 | 2021-12-31 | (69.79M) | — |
EBITDA vs competitors
How FDMT compares with its peers on the latest reported figures
- FDMT's LTM Mar 2026 EBITDA of -$163.43M is the 6th highest of the 8 companies compared; the peer median is -$95.72M.
- Its year-over-year change of +3.9% is the 5th highest of 8, against a peer median of +6.4%.
- EBITDA amounts to 185.2% of revenue for FDMT, versus a peer median of 505.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $73.43M | +298.8% | — | 505.0% | |
| LTM Mar 2026 | -$64.18M | -19.1% | — | 1437.5% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$85.19M | +20.5% | — | — |
| LTM Mar 2026 | -$95.72M | +32.5% | — | 120.0% | |
| LTM Mar 2026 | -$129.14M | +6.4% | — | 713.8% | |
| LTM Mar 2026 | -$163.43M | +3.9% | — | 185.2% | |
| LTM Mar 2026 | -$190.1M | -38.9% | — | — | |
| LTM Mar 2026 | -$229.35M | -87.3% | — | 261.2% | |
| Peer median (excluding FDMT) | -$95.72M | +6.4% | — | 505.0% | |
Competitors are the stored peer set for FDMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 18.04M | 3.13M | 20.72M | 37K | 85.21M |
| Cost of Revenue | 61.36M | 80.25M | 97.1M | 141.3M | 7.63M |
| Gross Profit | (43.32M) | (77.12M) | (76.37M) | (141.26M) | 77.58M |
| Gross Margin | -240.2% | -2464.8% | -368.5% | -381789.2% | 91.1% |
| Research & Development | 61.36M | 80.25M | 97.1M | 141.3M | 195.7M |
| Selling, General & Admin | 28.01M | 32.91M | 36.49M | 46.58M | 49.06M |
| Operating Expenses | 28.01M | 32.91M | 36.49M | 46.58M | 237.13M |
| Depreciation & Amortization | 1.52M | 2.4M | 4.2M | 6.71M | 7.63M |
| EBITDA | (69.79M) | (105.09M) | (96.63M) | (154.16M) | (132.48M) |
| EBITDA Margin | -386.9% | -3358.6% | -466.3% | -416656.8% | -155.5% |
| Operating Income | (71.33M) | (110.03M) | (112.87M) | (187.84M) | (159.55M) |
| Operating Margin | -395.5% | -3516.5% | -544.6% | -507678.4% | -187.2% |
| Interest Income | 137K | 2.57M | 12.21M | 27.05M | 19.48M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 16K | 2.54M | 12.03M | 26.97M | 19.44M |
| Income Before Tax | (71.32M) | (107.49M) | (100.84M) | (160.87M) | (140.11M) |
| Pre-Tax Margin | -395.4% | -3435.4% | -486.6% | -434778.4% | -164.4% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (71.32M) | (107.49M) | (100.84M) | (160.87M) | (140.11M) |
| Net Margin | -395.4% | -3435.4% | -486.6% | -434778.4% | -164.4% |
| EPS (Basic) | (2.46) | (3.12) | (2.58) | (2.98) | (2.42) |
| EPS (Diluted) | (2.46) | (3.12) | (2.58) | (2.98) | (2.42) |
| Weighted Avg Shares | 27.73M | 32.35M | 39.13M | 53.94M | 57.93M |
| Weighted Avg Shares (Diluted) | 27.73M | 32.35M | 39.13M | 53.94M | 57.93M |
4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
Intrinsic Alpha fair value
Locked
Current Price
$10.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.